Cost-effectiveness analysis of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer
Year: 2024
Type: article
Authors: YuQi Shang, Hao Guo
Institutions: Inner Mongolia People's Hospital, Baotou Medical College
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: closed
OpenAlex ID: W4404137801